Biogen
Search results
Ionis is building an extraordinary team and culture that is driven to deliver transformational medicines that pioneer new markets or fundamentally change the standard of care.
As the leader in RNA-targeted therapeutics for more than three decades, Ionis has focused every moment on advancing drug discovery, development, and providing hope for patients.
1 day ago · Ionis currently has five marketed medicines and a leading pipeline in neurology, cardiology, and other areas of high patient need. As the pioneer in RNA-targeted medicines, Ionis continues to drive innovation in RNA therapies in addition to advancing new approaches in gene editing.
Ionis Pharmaceuticals, Inc. is a biotechnology company based in Carlsbad, California, that specializes in discovering and developing RNA-targeted therapeutics.
With approved first-in-class medicines and up to a dozen more in mid- or late-stage development, our therapeutic breakthroughs are poised to transform lives.
Jun 18, 2024 · Ionis poised for continued momentum in 2024 with product launches and key advances in robust pipeline of investigational medicines for serious diseases
Mar 13, 2024 · CARLSBAD, Calif., March 13, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced positive results from a Phase 2 study of ION224, an investigational DGAT2 antisense inhibitor in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), previously referred to as nonalcoholic steatohepatitis ...
Jan 8, 2024 · In 2023, Ionis made significant progress in advancing a steady cadence of medicines for people with serious diseases, including the U.S. approval of WAINUA™ (eplontersen) for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis (ATTRv-PN) and the accelerated approval of QALSODY ® (tofersen) for SOD-1 amyotrophic ...
May 16, 2024 · Ionis plans to move ION582 into pivotal trial. Detailed ION582 data to be presented at upcoming medical meeting. CARLSBAD, Calif., May 16, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced positive topline data from the HALOS Phase 1/2a open-label study of ION582 in Angelman syndrome.
Jul 22, 2024 · Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced positive results from the completed multiple ascending dose (MAD) portion of the Phase 1/2 open-label study of ION582 in people with ...
